破坏PDE3A与SERCA2结合可增强SERCA2活性并降低慢性心衰小鼠死亡率
本研究探讨PDE3A与SERCA2的相互作用及其对SERCA2活性的影响。通过多种分子生物学方法,发现PDE3A直接结合SERCA2并抑制其活性,破坏该结合可增强SERCA2活性。在148只小鼠的随机盲法对照实验中,使用干扰肽OptF可降低主动脉结扎后20周的心脏死亡率并改善收缩功能。
要点
- PDE3A与SERCA2直接结合并抑制其活性,不依赖PDE3A催化活性。
- 干扰肽OptF破坏PDE3A/SERCA2结合,增强SERCA2活性。
- rAAV9-OptF治疗降低主动脉结扎小鼠20周心脏死亡率并改善收缩力。
核心结论
- PDE3A通过直接结合调控SERCA2活性,独立于其催化活性。
- 靶向SERCA2/PDE3A相互作用可预防主动脉结扎后心脏死亡,可能通过改善收缩力实现。
研究设计与样本
- 研究使用共聚焦显微镜、双色直接随机光学重建显微镜、邻位连接试验、免疫沉淀、肽阵列和表面等离子共振研究SERCA2与PDE3A在心肌细胞中的共定位及相互作用位点。
- 在148只小鼠中进行两项连续随机、盲法、对照的临床前试验,注射rAAV9-OptF、rAAV9-Ctrl或PBS后行主动脉结扎或假手术,随访20周。
主要发现
- PDE3A在人非衰竭、衰竭心脏及啮齿类心肌中与SERCA2共定位。
- PDE3A的氨基酸277-402直接结合SERCA2的氨基酸169-216(位于actuator结构域)。
- 破坏PDE3A与SERCA2结合可增加正常和衰竭心肌细胞中SERCA2活性。
- 干扰肽在蛋白激酶A抑制剂存在下及受磷蛋白缺陷小鼠中仍增加SERCA2活性,在心肌细胞特异性SERCA2失活小鼠中无效应。
- rAAV9-OptF治疗相比rAAV9-Ctrl降低心脏死亡率(风险比0.26 [95%CI 0.11-0.63]),相比PBS降低死亡率(风险比0.28 [95%CI 0.09-0.90])。
临床怎么用
- 针对SERCA2/PDE3A相互作用的干扰肽可能成为慢性心力衰竭治疗策略。
- OptF肽通过增强SERCA2活性改善收缩功能并降低死亡率,需进一步临床研究验证。
局限性
- 研究为临床前小鼠实验,结果尚未在人体中验证。
- 研究未报告干扰肽的剂量、给药方案及长期安全性数据。
- 研究未提供样本量计算或P值等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing SERCA2 (sarco[endo]-plasmic reticulum Ca2+ ATPase 2) activity is suggested to be beneficial in chronic heart failure, but no selective SERCA2-activating drugs are available. PDE3A (phosphodiesterase 3A) is proposed to be present in the SERCA2 interactome and limit SERCA2 activity. Disruption of PDE3A from SERCA2 might thus be a strategy to develop SERCA2 activators. METHODS: Confocal microscopy, 2-color direct stochastic optical reconstruction microscopy, proximity ligation assays, immunoprecipitations, peptide arrays, and surface plasmon resonance were used to investigate colocalization between SERCA2 and PDE3A in cardiomyocytes, map the SERCA2/PDE3A interaction sites, and optimize disruptor peptides that release PDE3A from SERCA2. Functional experiments assessing the effect of PDE3A-binding to SERCA2 were performed in cardiomyocytes and HEK293 vesicles. The effect of SERCA2/PDE3A disruption by the disruptor peptide OptF (optimized peptide F) on cardiac mortality and function was evaluated during 20 weeks in 2 consecutive randomized, blinded, and controlled preclinical trials in a total of 148 mice injected with recombinant adeno-associated virus 9 (rAAV9)-OptF, rAAV9-control (Ctrl), or PBS, before undergoing aortic banding (AB) or sham surgery and subsequent phenotyping with serial echocardiography, cardiac magnetic resonance imaging, histology, and functional and molecular assays. RESULTS: PDE3A colocalized with SERCA2 in human nonfailing, human failing, and rodent myocardium. Amino acids 277-402 of PDE3A bound directly to amino acids 169-216 within the actuator domain of SERCA2. Disruption of PDE3A from SERCA2 increased SERCA2 activity in normal and failing cardiomyocytes. SERCA2/PDE3A disruptor peptides increased SERCA2 activity also in the presence of protein kinase A inhibitors and in phospholamban-deficient mice, and had no effect in mice with cardiomyocyte-specific inactivation of SERCA2. Cotransfection of PDE3A reduced SERCA2 activity in HEK293 vesicles. Treatment with rAAV9-OptF reduced cardiac mortality compared with rAAV9-Ctrl (hazard ratio, 0.26 [95% CI, 0.11 to 0.63]) and PBS (hazard ratio, 0.28 [95% CI, 0.09 to 0.90]) 20 weeks after AB. Mice injected with rAAV9-OptF had improved contractility and no difference in cardiac remodeling compared with rAAV9-Ctrl after aortic banding. CONCLUSIONS: Our results suggest that PDE3A regulates SERCA2 activity through direct binding, independently of the catalytic activity of PDE3A. Targeting the SERCA2/PDE3A interaction prevented cardiac mortality after AB, most likely by improving cardiac contractility.
引用
- Skogestad, Albert, Hougen, et al. Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure. Circulation. 2023. PMID: 36876489. doi:10.1161/CIRCULATIONAHA.121.054168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。